Dr Mark Cooksey – CEO & Managing Director – ABx Group (ASX:ABX) is a uniquely positioned, Australian company delivering materials for a cleaner future. The two current areas of focus are the creation of an ionic adsorption clay rare earth project in northern Tasmania and the establishment of a plant to produce hydrogen fluoride and aluminium fluoride from recycled industrial waste, to replace imports (ALCORE).
Copyright 2024 – Finance News Network
27 Sep 2021 - PropTech Group Limited (ASX:PTG) CEO and Managing Director Joe Hanna introduces the company's suite of market-leading real estate software solutions, discussing FY21 results and outlook.
31 Aug 2020 - Sequoia Financial Group Limited (ASX:SEQ) Managing Director & CEO Garry Crole talks about the company's group strategy, outlook, and much improved FY20 results, despite the challenging operating environment.
10 Jan 2020 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, discusses funding for the Novatti's banking subsidiary, its banking licences and its core customer acquisition proposition.
17 Apr 2023 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the possibility of falling inflation, immigration and the tight labour market, and the outlook for the equity market.
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
10 Oct 2023 - Jon Price - Managing Director - Richmond Vanadium Technology (ASX:RVT) is an Australian minerals development company which is advancing the Richmond – Julia Creek Vanadium Project in Queensland through a Bankable Feasibility Study.
28 Apr 2020 - BrainChip Holdings (ASX:BRN BrainChip Holdings (ASX:BRN) CEO Lou DiNardo talks about its Akida integrated circuit, its advantages in event-based convolutional (e-conv) networks, applications and its move to wafer production and first engineering samples by Q3 2020.
02 Oct 2024 - Lithium Universe Limited (ASX:LU7) CEO Alex Hanly discusses the company's prefeasibility study, operational costs and development timeline.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
